Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 5/20 | 0.39 |
| ▸ | GLB1 | P16278 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.31 |
| ▸ | GUSB | P08236 | 1/20 | 0.31 |
| ▸ | GANAB | Q14697 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27583222 | 1.00 | GBA1 (0.39) | GBA1GLB1CA1CA2CA4 | |
| SCHEMBL27583223 | 1.00 | GBA1 (0.39) | GBA1GLB1CA1CA2CA4 | |
| SCHEMBL24862658 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL21598800 | 0.80 | GBA1 (0.38) | GBA1GLB1SHBGGANAB | |
| SCHEMBL3477738 | 0.78 | SLC6A2 (0.34) | GBA1CA1CA2CA4GANAB | |
| SCHEMBL13483776 | 0.76 | GLB1 (0.32) | GBA1GLB1OPRM1OPRK1 | |
| SCHEMBL2896865 | 0.75 | — | — | |
| SCHEMBL4559444 | 0.75 | — | — | |
| SCHEMBL3928808 | 0.75 | — | — | |
| SCHEMBL17798814 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110191882-A | Novel heterocyclic compounds, preparation method and the pharmaceutical composition comprising it | 株式会社大熊制药 | 2019-08-30 | — | — | CN | claimed |
| US-12569679-B2 | Treatment delivery system | WearOptimo Pty Ltd (AU) | 2026-03-10 | — | — | US | disclosed |
| US-12484814-B2 | Actuator system | WearOptimo Pty Ltd (AU) | 2025-12-02 | — | — | US | disclosed |
| US-20250025078-A1 | ELECTRODE ARRANGEMENT | WearOptimo Pty Ltd (AU) | 2025-01-23 | — | — | US | disclosed |
| US-20230053962-A1 | ANALYTE MEASUREMENT SYSTEM | WearOptimo Pty Ltd (AU) | 2023-02-23 | — | — | US | disclosed |
| US-20220346679-A1 | ANALYTE MEASUREMENT SYSTEM | WearOptimo Pty Ltd (AU) | 2022-11-03 | — | — | US | disclosed |
| EP-4037552-A1 | ANALYTE MEASUREMENT SYSTEM | Wearoptimo Pty Ltd (AU) | 2022-08-10 | — | — | EP | disclosed |
| US-20210402182-A1 | TREATMENT DELIVERY SYSTEM | WearOptimo Pty Ltd (AU) | 2021-12-30 | — | — | US | disclosed |
| US-20210386373-A1 | ANALYTE DETECTION SYSTEM | WearOptimo Pty Ltd (AU) | 2021-12-16 | — | — | US | disclosed |
| US-20210338158-A1 | MEASUREMENT SYSTEM | WearOptimo Pty Ltd (AU) | 2021-11-04 | — | — | US | disclosed |
| WO-2020069569-A1 | ACTUATOR SYSTEM | WearOptimo Pty Ltd (AU) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020069565-A1 | MEASUREMENT SYSTEM | WearOptimo Pty Ltd (AU) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020069567-A1 | ELECTRODE ARRANGEMENT | WearOptimo Pty Ltd (AU) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020069568-A1 | TREATMENT DELIVERY SYSTEM | WearOptimo Pty Ltd (AU) | 2020-04-09 | — | — | WO | disclosed |
| WO-2020069570-A1 | ANALYTE DETECTION SYSTEM | WearOptimo Pty Ltd (AU) | 2020-04-09 | — | — | WO | disclosed |
| CN-110191882-A | Novel heterocyclic compounds, preparation method and the pharmaceutical composition comprising it | 株式会社大熊制药 | 2019-08-30 | — | — | CN | disclosed |
| CN-101991100-B | Health-care food for removing three toxins in human body, beautifying and resisting senium as well as preparation method thereof | TIANJIN TAIREN BIOTECHNOLOGY CO LTD | 2012-08-22 | — | — | CN | disclosed |
| CN-101991100-A | Health-care food for removing three toxins in human body, beautifying and resisting senium as well as preparation method thereof | TIANJIN TAIREN BIOTECHNOLOGY CO LTD | 2011-03-30 | — | — | CN | disclosed |
| WO-2010131058-A1 | PRODUCT FOR THE PROTECTION AGAINST HONEYBEE MITES, AND METHOD FOR THE PREPARATION OF THE ACTIVE SUBSTANCE | VON BARTHELDNE ABRI JUDIT (HU) | 2010-11-18 | — | — | WO | disclosed |
| US-20100098788-A1 | Extracts of Curcuma and Methods of Use Thereof | HERBALSCIENCE GROUP, LLC | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569679-B2 | Treatment delivery system | PIEZO1, DSG1, KRT18 | GBA1 1123/4885GLB1 3841/4885CA1 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.